Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Camidge, D. Ross , Demedts, Ingel , Grosch, Heidrun, Mercurio, Jean-Pierre Di , Molina, Julian R. , Bepler, Gerold , Lewanski, C., Wijayawardana, Sameera R. , Wang, Xuejing Aimee , Morán, Teresa , Mileham, Kathryn Finch , Juan, Óscar , Goldman, Jonathan W. , Park, Keunchil , Wallin, Johan Erik , Wacheck, Volker , Smit, Egbert F

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070

10.1200/jco.2016.34.15_suppl.9070 Get It

Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).
Sicotte, Hugues , Carlson, Rachel E. , Tan, Winston , Wu, Kevin J. , Eiken, Patrick W. , Jiménez, Rafael E. , Cernigliaro, Joseph G. , Costello, Brian A. , Pitot, Henry C., Moynihan, Timothy J. , Wang, Liewei , Kohli, Manish , Hillman, David W. , Wang, Liguo , Li, Ying , Quevedo, Fernando , Ho, Thai H. , Bryce, Alan H. , Dehm, Scott M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5036-5036

10.1200/jco.2016.34.15_suppl.5036 Get It

Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.
Ramanathan, Ramesh K., Wang, Lan , Fan, Xiaolin , Motwani, Monica, Wong, Shekman, Morgan-Lappe, Susan E. , Iyer, Suhasini , Naumovski, Louie, Gordon, Michael S. , Nemunaitis, John , Sledge, George W. , Strickler, John H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2507-2507

10.1200/jco.2016.34.15_suppl.2507 Get It

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).
Pomerantz, Mark M., Wang, Victoria , Lee, Gwo‐Shu Mary , Hahn, Noah M. , Jarrard, David F. , Liu, Glenn , García, Jorge A. , DiPaola, Robert S. , Freedman, Matthew L. , Kantoff, Philip W. , Xie, Wanling , Kohli, Manish , Wang, Elaine, Chen, Yu‐Hui , Carducci, Michael A. , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1540-1540

10.1200/jco.2016.34.15_suppl.1540 Get It

Representation of minorities in oncology clinical trials: Review of the past 14 years.
Duma, Narjust , Aguilera, Jesus Vera, Leventakos, Konstantinos , Adjei, Alex A. , Paludo, Jonas , Wang, Yucai , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 2533-2533

10.1200/jco.2017.35.15_suppl.2533 Get It

2533 Background: Many cancer clinical trials (CT) lack appropriate representation of specific patients populations, limiting the generalizability of the evidence obtained. Therefore, we determined the representation of ethnic minorities in oncology CT. Methods: Enrollment data from all therapeutic trials reported as completed in clinicaltrial.gov from 2003 to 2016 were analyzed. CT in rare cancers (< 1% incidence) or with recruitment outside of the US were excluded. Enrollment fraction (EF) was defined as the number of enrollees divided by the 2013 SEER database cancer prevalence. Chi-square test was used to estimate differences in categorical data. Results: Out of 1,012 CT, 310 (31%) reported ethnicity with a total of 55689 enrollees. Distribution by race and comparison with data from 1996-2002, US cancer prevalence and US census are described in the Table. Participation in CT varied significantly across ethnic groups, non-Hispanic Whites (NHW) were more likely to be enrolled in CT (EF of 1.2%) than African Americans (EF of 0.7%, p < 0.001) and Hispanics (EF of 0.4%, p<0.001). A decrease in African Americans (AA) and Hispanics (H) enrollment was observed when compared with historical data from 1996 to 2002. Hispanics were less represented in breast and prostate cancer CT contributing only to 3% and 1.5% of the study population; African Americans were less represented in lung (5.4%) and renal cell carcinoma (3%) trials. Asians were well represented and their recruitment doubled over the past 14 years (2% vs 5.3%). Conclusions: African Americans and Hispanics were less likely to be enrolled in CT. Comparing with historical data; we observed a decrease in minorities’ recruitment in the past 14 years. This change could be attributed to the increased complexity of CT and mandatory molecular testing as many minorities lack access to institutions with genetic testing capacity. Future trials should take extra measures to recruit participants that adequately represent the U.S. cancer population. [Table: see text]
Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
Ross, Helen J. , Kozono, David , Urbanic, James J., DuFrane, Carter, Bāra, Ilze, Gandhi, Mayank , Schulze, Katja , Brockman, Jane Michelle, Wang, Xiaofei F., Stinchcombe, Tom, Kozono, David E , Williams, Terence M. , Vokes, Everett E. , Stinchcombe, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8585-TPS8585

10.1200/jco.2018.36.15_suppl.tps8585 Get It

Rituximab maintenance for mantle cell lymphoma: A meta-analysis.
Almader‐Douglas, Diana , Reeder, Craig B. , Jain, Tania , Jain, Tania , Hilal, Talal , Wang, Zhen , Rosenthal, Allison

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e19557-e19557

10.1200/jco.2018.36.15_suppl.e19557 Get It

Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS).
Secreto, Charla, Call, Timothy G. , Leis, José F., Feldman, Andew L., Ansell, Stephen M. , He, Rong , Wang, Yucai , Sinha, Sutapa , Dong, Haidong , Parikh, Sameer A. , Rech, Karen L. , Kenderian, Saad S. , Kay, Neil E. , Ding, Wei

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7524-7524

10.1200/jco.2018.36.15_suppl.7524 Get It

Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.
Kommoss, Stefan , Winterhoff, Boris , Aliferis, Constantin , Burges, Alexander , Canzler, Ulrich , Wang, Jinhua , Belau, Antje , Hanker, Lars , Ma, Sisi , Hilpert, Felix , Tourani, Roshan , Kimmig, Rainer , Kurzeder, Christian , Schmalfeldt, Barbara , Dowdy, Sean C. , Pfisterer, Jacobus , Heitz, Florian , Wang, Chen , Ma, Sisi , Sehouli, Jalid , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5550-5550

10.1200/jco.2018.36.15_suppl.5550 Get It

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.
Kommoss, Stefan , Winterhoff, Boris , Wang, Chen , Aliferis, Constantin , Kimmig, Rainer , Wang, Jinhua , Ma, Sisi , Gregorio, Nikolaus de , Mahner, Sven� , Tourani, Roshan , Park‐Simon, Tjoung‐Won , Baumann, Klaus , Taran, Florin‐Andrei , Kommoss, Friedrich, Schroeder, W., Dowdy, Sean C. , Pfisterer, Jacobus , Heitz, Florian , Sehouli, Jalid , Ma, Sisi , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5520-5520

10.1200/jco.2018.36.15_suppl.5520 Get It